Trends in Venous Thromboembolism Readmission Rates after Ischemic Stroke and Intracerebral Hemorrhage.
Acute stroke
Deep venous thrombosis
Pulmonary embolism
Venous thromboembolism
Journal
Journal of stroke
ISSN: 2287-6391
Titre abrégé: J Stroke
Pays: Korea (South)
ID NLM: 101602023
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
08
07
2022
accepted:
08
09
2022
pubmed:
3
1
2023
medline:
3
1
2023
entrez:
2
1
2023
Statut:
ppublish
Résumé
Venous thromboembolism (VTE) is a life-threatening complication of stroke. We evaluated nationwide rates and risk factors for hospital readmissions with VTE after an intracerebral hemorrhage (ICH) or acute ischemic stroke (AIS) hospitalization. Using the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database, we included patients with a principal discharge diagnosis of ICH or AIS from 2016 to 2019. Patients who had VTE diagnosis or history of VTE during the index admission were excluded. We performed Cox regression models to determine factors associated with VTE readmission, compared rates between AIS and ICH and developed post-stroke VTE risk score. We estimated VTE readmission rates per day over a 90-day time window post-discharge using linear splines. Of the total 1,459,865 patients with stroke, readmission with VTE as the principal diagnosis within 90 days occurred in 0.26% (3,407/1,330,584) AIS and 0.65% (843/129,281) ICH patients. The rate of VTE readmission decreased within first 4-6 weeks (P<0.001). In AIS, cancer, obesity, higher National Institutes of Health Stroke Scale (NIHSS) score, longer hospital stay, home or rehabilitation disposition, and absence of atrial fibrillation were associated with VTE readmission. In ICH, longer hospital stay and rehabilitation disposition were associated with VTE readmission. The VTE rate was higher in ICH compared to AIS (adjusted hazard ratio 2.86, 95% confidence interval 1.93-4.25, P<0.001). After stroke, VTE readmission risk is highest within the first 4-6 weeks and nearly three-fold higher after ICH vs. AIS. VTE risk is linked to decreased mobility and hypercoagulability. Studies are needed to test short-term VTE prophylaxis beyond hospitalization in high-risk patients.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Venous thromboembolism (VTE) is a life-threatening complication of stroke. We evaluated nationwide rates and risk factors for hospital readmissions with VTE after an intracerebral hemorrhage (ICH) or acute ischemic stroke (AIS) hospitalization.
METHODS
METHODS
Using the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database, we included patients with a principal discharge diagnosis of ICH or AIS from 2016 to 2019. Patients who had VTE diagnosis or history of VTE during the index admission were excluded. We performed Cox regression models to determine factors associated with VTE readmission, compared rates between AIS and ICH and developed post-stroke VTE risk score. We estimated VTE readmission rates per day over a 90-day time window post-discharge using linear splines.
RESULTS
RESULTS
Of the total 1,459,865 patients with stroke, readmission with VTE as the principal diagnosis within 90 days occurred in 0.26% (3,407/1,330,584) AIS and 0.65% (843/129,281) ICH patients. The rate of VTE readmission decreased within first 4-6 weeks (P<0.001). In AIS, cancer, obesity, higher National Institutes of Health Stroke Scale (NIHSS) score, longer hospital stay, home or rehabilitation disposition, and absence of atrial fibrillation were associated with VTE readmission. In ICH, longer hospital stay and rehabilitation disposition were associated with VTE readmission. The VTE rate was higher in ICH compared to AIS (adjusted hazard ratio 2.86, 95% confidence interval 1.93-4.25, P<0.001).
CONCLUSIONS
CONCLUSIONS
After stroke, VTE readmission risk is highest within the first 4-6 weeks and nearly three-fold higher after ICH vs. AIS. VTE risk is linked to decreased mobility and hypercoagulability. Studies are needed to test short-term VTE prophylaxis beyond hospitalization in high-risk patients.
Identifiants
pubmed: 36592970
pii: jos.2022.02215
doi: 10.5853/jos.2022.02215
pmc: PMC9911841
doi:
Types de publication
Journal Article
Langues
eng
Pagination
151-159Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Références
Ann Pharmacother. 2009 Jun;43(6):1064-83
pubmed: 19458109
Blood Adv. 2019 Dec 10;3(23):3898-3944
pubmed: 31794602
Thromb Res. 2007;119(3):265-74
pubmed: 16674999
Stroke. 1991 Jun;22(6):760-2
pubmed: 2057976
Arch Intern Med. 2008 Aug 11;168(15):1678-83
pubmed: 18695082
Health Serv Res. 2014 Feb;49(1):284-303
pubmed: 23855598
Blood. 2013 Sep 5;122(10):1712-23
pubmed: 23908465
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Circulation. 2020 Jun 16;141(24):e914-e931
pubmed: 32375490
Health Serv Res. 2014 Oct;49(5):1701-20
pubmed: 24779867
Chest. 2012 Feb;141(2 Suppl):e195S-e226S
pubmed: 22315261
Clin Epidemiol. 2020 Sep 25;12:1007-1013
pubmed: 33061648
J Am Heart Assoc. 2016 Nov 7;5(11):
pubmed: 27821402
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
Am J Phys Med Rehabil. 2003 May;82(5):364-9
pubmed: 12704275
Stroke. 2001 Jan;32(1):262-7
pubmed: 11136946
J Neurol Sci. 2020 Feb 15;409:116618
pubmed: 31837536
Neoplasia. 2002 Nov-Dec;4(6):465-73
pubmed: 12407439
BMJ. 2019 May 22;365:l1778
pubmed: 31122927
Stroke. 2015 Feb;46(2):369-75
pubmed: 25572413
Acta Med Scand. 1987;222(5):401-8
pubmed: 3425392
Am J Cardiol. 2005 Dec 15;96(12):1731-3
pubmed: 16360366
J Thromb Haemost. 2011 Nov;9(11):2193-200
pubmed: 21883879
Am J Med. 2005 Sep;118(9):978-80
pubmed: 16164883
Scand J Rheumatol. 2023 Mar;52(2):111-117
pubmed: 35023437
Drugs Context. 2019 Jan 21;8:212568
pubmed: 30719052
Am J Med. 2006 Jan;119(1):60-8
pubmed: 16431186
IMJ Ill Med J. 1984 May;165(5):328-32
pubmed: 6145691